Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc.
1500 Broadway
Suite 1401
New York, NY 10036
United States
332 208 6102
https://www.nuvationbio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 51
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. David T. Hung M.D. | Founder, President, CEO & Director | 1M | N/D | 1958 |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer | 694.56k | N/D | 1967 |
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer | 677.15k | N/D | 1970 |
| Mr. Moses Makunje CPA | VP of Finance and Principal Accounting & Financial Officer | N/D | N/D | 1979 |
| Ms. Stacy Markel | Chief People Officer | N/D | N/D | 1965 |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer | 586.04k | N/D | 1970 |
| Ms. Kerry A. Wentworth | Chief Regulatory Officer | N/D | N/D | 1973 |
| Ms. Colleen Sjogren | Chief Commercial Officer | N/D | N/D | 1970 |
| Dr. Junyuan Wang Ph.D. | CEO & Co-Founder of AnHeart Therapeutics and Director | N/D | N/D | 1973 |
Descripción
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Nuvation Bio Inc. a partir del 1 de mayo de 2024 es 10. Las puntuaciones principales son Auditoría: 7; Junta: 7; Derechos del accionista: 10; Compensación: 10.
